After a few of days speculation and rumors, Australia-headquartered biotech CSL Limited (ASX: CSL) today confirmed it has entered into a definitive agreement to acquire Switzerland-based Vifor Pharma (VTX: FIFoN), a specialty pharmaceutical company with leadership in iron deficiency, nephrology and cardio-renal therapies.
CSL has made an offer of $179.25 (167 Swiss francs) per share, payable in US dollars, a premium of 61% to Vifor’s unaffected closing price on December 1, for an aggregate equity value for Vifor Pharma of $ 11.7 billion/10.9 billion francs. The tender is currently expected to commence around January 18, 2022 and the transaction is expected to complete around mid-2022.
Vifor’s shares, which had already risen earlier this month on the basis of the rumors, were up 11.8% at 156.90 francs by late afternoon today.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze